# Brandon BioCatalyst

> Brandon BioCatalyst is a VC fund in Melbourne backing Biotechnology and Medical. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Melbourne, Australia
- Total investments: 9
- Last investment: May 2024
- Lead investor: 89%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/brandon-capital
- Website: https://brandonbiocatalyst.com

Brandon BioCatalyst is a VC fund in Melbourne focused on Biotechnology and Medical. The largest life science investment fund in Australia and New Zealand is Brandon BioCatalyst. We are a groundbreaking partnership involving major Australian superannuation funds, CSL, the governments of Australia and New Zealand, state governments in Australia, and more than 50 esteemed medical research institutions and hospitals.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 67% |
| Medical | 4 | 44% |
| Health Care | 3 | 33% |
| Therapeutics | 3 | 33% |
| Biopharma | 2 | 22% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Grant | 6 | 67% |
| Venture - Series Unknown | 2 | 22% |
| Series B | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Australia | 6 | 67% |
| Israel | 1 | 11% |
| United Kingdom | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Currus Biologics | Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers. |  | Venture - Series Unknown | May 07, 2024 |  |
| Respirion Pharmaceuticals | Founded in 2018, Respirion Pharmaceuticals is an early-stage biotechnology company focused on developing new treatments for respiratory disease. The Company is a spinout from the Telethon Kids Institute in Perth where the product development was incubated.Respirion’s lead product, an inhaled therapy for the life-threatening disease CysticFibrosis, has shown promising results in an early clinical study carried out with the Western Australian Department of Health.The Company has partnered with Australia’s largest life science investment fund, the Medical Research Commercialisation Fund, and the US Cystic Fibrosis Foundation to conduct further clinical trials in Australia and the US. |  | Grant | May 07, 2024 |  |
| Ena Respiratory | Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs. |  | Grant | May 07, 2024 |  |
| Cincera Therapeutics | Cincera Therapeutics is a privately held biotechnology company. | $327.2K | Grant | May 24, 2023 |  |
| OccuRx | OccuRx, a Melbourne-based biopharmaceutical company, was established in 2014 with venture funding from the Medical Research Commercialisation Fund, Brandon Capital Partners and Uniseed. The Company’s primary focus is on the development of innovative therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis. | $14.5M | Series B | Sep 06, 2022 |  |
| Azura Ophthalmics | Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S. |  | Grant | Aug 17, 2022 |  |
| Denteric | Denteric is developing a vaccine based on research conducted at the University of Melbourne, with collaborative support from CSL Limited, to fight the disease and will receive the money in three parts each year from 2019 to 2021. |  | Grant | Jul 20, 2022 |  |
| George Medicines | George Medicines is a drug manufacturing company that improves the management of non-communicable diseases. | $1M | Venture - Series Unknown | Jul 20, 2022 |  |
| OccuRx | OccuRx, a Melbourne-based biopharmaceutical company, was established in 2014 with venture funding from the Medical Research Commercialisation Fund, Brandon Capital Partners and Uniseed. The Company’s primary focus is on the development of innovative therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis. | $1.5M | Grant | Jul 20, 2022 |  |

9 of 9 investments shown.

## Co-investors
- [Brandon Capital](https://shizune.co/investors/profile/brandon-capital-partners) — VC Fund, 6 deals together
- Medical Research Future Fund (MRFF) — VC Fund, 1 deal together
- [Uniseed](https://shizune.co/investors/profile/uniseed-vc) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund

## FAQ

### What does Brandon BioCatalyst invest in?

Brandon BioCatalyst invests primarily in Biotechnology, Medical and Health Care startups, most often at Grant and Venture - Series Unknown stage. Most of the 9 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Brandon BioCatalyst last invest?

The most recent investment recorded for Brandon BioCatalyst closed in May 2024. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co